Liyan Jiang, MD, PhD

Shanghai Chest Hospital, Jiao Tong University, Shanghai, China

Engaged in lung disease, lung cancer diagnosis and clinical trials. Dr. Jiang is a leader in differential diagnosis, multidisciplinary and individualized treatment.

Currently: Clinical Trials Director at Shanghai Chest Hospital, Deputy Director Clinical Research with Shanghai Chest Cancer Institute, Special Committee Chairman of the China Medical Education Association in lung cancer. Additional responsibilities; Executive director of China Medical Education Association, Deputy Head Chinese Medical Association Shanghai Respiratory Society lung cancer group, Director of lung cancer transformation medicine research department of Shanghai Institute of Respiratory Diseases, Standing Committee of the Chinese Medical Association of Integrative Medicine Respiratory Disease Committee, Vice Chair Shanghai Anti-Cancer Association Respiratory Endoscopy professional committee.

Member of the Editorial Board and clinical reviewer for; “International Journal of Respiratory Medicine”, “Anti-Cancer magazine”, “Annals of Oncology”, “Chinese Journal of lung cancer”, “The Clinical Respiratory Journal”, “Oncotarget”, “Cancer Letters”.

Her goal: To resolve the difficulties of initial diagnosis and apply effective treatments early. Combining new resources for a Translational Medicine approach.

A recently completed clinical study focused on the early screening of lung cancer; the non-small cell lung cancer-driven genes, drug-resistant genes, treatment-related gene dynamic changes; small cell lung cancer driver gene and treatment strategies. From pathogenesis developing molecular targeted therapies. Cooperating with international clinical trials of drugs provided a wealth of theoretical knowledge, experience and research data. Implementing database tools of Clinical Case Analysis relating clinical trial drug data within a larger lung cancer database model is providing researchers valuable tools for data mining and bioinformatics to better explore the difficulties of lung cancer.

Executive Director: Academic Committee of Thoracic Oncology Society (ACTOS)

Member: Chinese Society of Clinical Oncology (CSCO)

Member: American Society of Clinical Oncology (ASCO)